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Abstract
Background: Systemic sclerosis (SSc) is an autoimmune disease where controversy on Th1/Th2 balance dominates. We
investigated whether the recently discovered Th17 pattern was present in SSc.
Methodology and Principal Findings: Patients were subdivided as having limited cutaneous SSc (lcSSc, n = 12) or diffuse
cutaneous SSc (dcSSc, n = 24). A further arbitrary subdivision was made between early dcSSc (n = 11) and late dcSSc (n = 13)
based upon the duration of disease. As a comparator group 14 healthy controls were studied. CD3+ cells were isolated
using FACS and subsequently studied for the expression of CD4, CD8, CD25, CD45Ro, CD45Ra, IL-23, GITR, CD69 and
intracellular expression of IL-17, TGFb and IFNc using flow cytometry. Levels of IL-17, IL-6, IL-1a and IL-23 were measured
using Bioplex assays. SSc patients had more and more activated CD4+ cells. In addition, CD4, CD45Ro and CD45Ra cells from
all SSc patients highly expressed the IL23R, which was associated with a higher IL-17 expression as well. In contrast, IFNc
and TGFb were selectively up regulated in SSc subsets. In line with these observation, circulating levels of IL-17 inducing
cytokines IL-6, IL-23 and IL-1a were increased in all or subsets of SSc patients.
Conclusion and Significance: The combination of IL-17, IFNc and TGFb levels in CD45Ro and CD45Ra cells from SSc patients
is useful to distinguish between lSSc, ldSSc or edSSc. Blocking Th17 inducing cytokines such as IL-6 and IL-23 may provide a
useful tool to intervene in the progression of SSc.
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Introduction
Systemic Sclerosis (SSc) is a complex inflammatory autoimmune
disease characterized by excessive deposition of matrix molecules,
leading to fibrosis of multiple organs including the skin, lungs,
heart and gastrointestinal tract, and often leading to severe
morbidity and premature death. Although the role of immune
dysfunction in the pathogenesis of SSc is generally accepted, the
exact pathways that cause immune dysfunction in SSc remain to
be elucidated. Alterations in cellular immunity are typified by
aberrant T cell biology both in the skin as well as circulation of SSc
patients. For example, CD4+ T cells are increased in the
circulation of SSc patients [1,2] whereas NKT cells and c/d T
cells are decreased [3]. In addition, lesional skin from SSc patients
displays various features consistent with T cell activation [1,4,5].
Finally, T cell biology was altered in SSc in that the secretion of
various inflammatory mediators is markedly increased [6,7].
In this line the Th1/Th2 paradigm has been investigated by
studying the presence of Th1 (IL-12, IFNc) and Th2 (IL-4, IL-13 and
IL-10) associated cytokines in the circulation, in circulating cells and
in the skin of SSc patients. Driven by opposing findings, these studies
led controversy whether these Th1/Th2 profiles could explain the
pathogenesis of SSc. The recognition of IL-17 producing T cells
(Th17) has opened novel pathways to explain several features of SSc.
In general, T cell priming by professional antigen presenting cells is
tuned by inflammatory mediators, including TGFb, IL-6 and IL-12.
The combination of these cytokines determines the ultimate fate of
naive T cells. For instance, TGFb alone up regulates FoxP3
expression, a marker for T regulatory cells. In contrast, accumulating
evidence suggests that TGFb in combination with IL-1a, IL-6 or IL-
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23 drives the expression of RORct, a proliferation factor specific for
the recently identified Th17 subset [8,9,10,11]. Intriguingly, IL-23,
IL-1a and IL-17 have been found increased in the circulation of SSc
patients compared to healthy controls [12,13,14,15]. Together, these
observations suggest the potential for skewing of the Th17 axis in SSc.
Th17 cells are characterized by the production of IL-17A (IL-
17) and are thought to clear extracellular pathogens not effectively
cleared by either Th1 or Th2 cells. To this aim, Th17 cells appear
at sites of inflammation with rapid kinetics and possibly bridge the
gap between innate and adaptive immunity by attracting other Th
cells to the inflammatory site. Various recent studies have emerged
suggesting that Th17 cells are essential in autoimmune diseases.
First, mice deficient for the Th1 effector cytokine IFNc develop
enhanced experimental autoimmune encephalomyelitis (EAE)
[16], and the absence of IL-23, results in a lack of Th17 cells
and protection from EAE and collagen-induced arthritis (CIA)
[17,18]. Second, IL-17 has been found to be increased in patients
with rheumatoid arthritis [19], multiple sclerosis [20], inflamma-
tory bowel disease [21], psoriasis [11] and seronegative spondyl-
arthritides [22]. IL-17 has been involved in many pathological
features that play a role in SSc pathology including the secretion of
pro-inflammatory cytokines, the recruitment of monocytes and the
triggering of granulocyte-macrophage colony-stimulating factor
[23,24]. In light of fibrosis being the cardinal feature of SSc, it is
interesting to note that IL-17 has also been implicated in fibrosis of
the basal membrane in asthma [25] and the control of
inflammatory response after bleomycin-induce lung injury, a
model often exploited to study pulmonary fibrosis [26].
To address the possible role of IL17 in SSc, we investigated
Th17 cell frequency in the circulation of SSc patients, and the
expression of key cytokine regulators and markers of T cell
phenotypes, IFNc and TGFb. Because there are two clinically
distinct forms of systemic sclerosis and at least one of these forms
evolves over time, we evaluated Th17 cell frequency and cytokine
expression in three subgroups: patients with early compared to late
diffuse cutaneous SSc and patients with limited cutaneous SSc. We
found that circulating Th17 cells are significantly increased in all
three SSc patient subsets compared to healthy controls. In
addition, together with the expression of IL-17, clinical SSc
phenotypes were associated with specific patterns of intracellular
expression of TGFb and IFNc. Together these data indicate that
T cell priming in SSc is skewed towards the Th17 axis, which
together with intracellular staining for TGFb and IFNc provide a
novel markers of SSc phenotypes. Importantly, circulating levels of
IL-17 were undetectable whereas the Th17 inducing cytokines IL-
6 and IL-23 levels were increased in the circulation of SSc patients.
Methods
Study population
Cell-based In vitro experiments. Thirty-six patients
presenting to the Arthritis Center, Boston Medical Center were
included in the study (Table 1). All of the patients met the
American College of Rheumatology preliminary criteria for the
classification of SSc [27]. Patients were subdivided as having
limited cutaneous SSc (lcSSc, n = 12) or diffuse cutaneous SSc
(dcSSc, n = 24) on the basis of the extent of their skin involvement
[28]. A further subdivision was made between early dcSSc (n = 11)
and late dcSSc (n = 13) based upon the duration of disease,
defining early dcSSc as patients having a disease duration ,2
years and late dcSSc as patients having a disease duration longer
than 3 years. As a comparator group 14 healthy controls were
studied. Treatment was investigated 6 months before the study.
Measurement of circulating cytokines. For the measure-
ment of circulating levels of TNFa, IL-6 and IFNc plasma from
healthy controls (n = 28) and 177 SSc patients (lSSc n = 110, ldSSc
n = 34, edSSc n = 33) from the Boston University Area (similar to
those included in the in vitro studies), the Radboud University
Nijmegen Medical Center area (RUMC) and Lund University
Hospital area were analyzed. Blood and plasma samples were
obtained with approval by written informed consent under
Institutional Review Board approval protocols at all three
academic centers involved.
Table 1. Clinical characteristics of patients included in in vitro assays.
Limited cutaneous SSc Late diffuse cutaneous SSc Early diffuse cutaneous SSc
Number 12 11 13
N females (%) 10 (83) 9 (82) 11 (85)
Age at onset 42.6612.3 40.6611.2 44.3610.2
Disease duration 9.167.8 7.967.1 1.160.7
ANA positivity 100% 73% 92%
mRSS at inclusion not assessed 15.868.3* 22.268.5*
Pulmonary hypertension 33% 18% 15%
Lung fibrosis 25% 45% 31%
Current Therapies
MMF 0% 36% 30%
Cyclophosphamide 0% 18% 15%
Prednisolone 25% 28% 53%
Hydroxychloroquine 17% 9% 0%
anti-IL-3 0% 0% 8%
Methotrexate 0% 0% 0%
Tacrolimus 8% 0% 0%
*0.03.
doi:10.1371/journal.pone.0005903.t001
Th17 Cells in SSc
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Monoclonal antibodies
For immunostaining and analysis by fluorescence-activated cell
sorting (FACS), we used phycoerythrin (PE), allophycocyanin
(APC) and fluorescein isothiocynate (FITC) conjugated mouse
monoclonal antibodies (mAb) against human CD4, CD8, GITR,
CD69, IL-23R, CD45Ro, CD45Ra, and CD25 (Miltenyi Biotec
Inc., CA, USA). Intracellular staining of CD45Ro, CD45Ra or
CD25+ cells for IL-17, TGFb and IFNc was performed using the
intracellular staining procedure according to the manufacturer’s
protocols. Corresponding mouse/rat isotype controls were includ-
ed in all analyses.
Isolation of PBMCs, CD3+ cells and flow cytometry
PBMCs were isolated from heparinized venous blood by using
density-gradient centrifugation over Ficoll-Paque (Amersham Biosci-
ence). Next, CD3+ cells were isolated from PBMCs using CD3
microbeads according to manufacturer’s protocol (Miltenyi Biotec).
After isolation, cells were directly transferred into RPMI 1640 media
supplemented with 2 nM L-glutamine, 100 U/mL/ml penicillin/
streptomycin (Life technologies), and 10% FBS (BioWhitacker) in 96-
well U-bottom plates (Nunc). For flowcytometric analysis, CD3+
were kept on ice and washed extensively with citrated PBS containing
1% FCS. 10 ml of FITC, APC or PE- conjugated antibody was added
and incubated on ice for 20 min. 300 ml FACS buffer was added and
T cells were pelleted, resuspended in 200 ml buffer. Thereafter, cells
were washed in buffer, fixed with 2% formaldehyde, washed again in
buffer and stored at 4uC. The cells were analyzed using a LSRII
FACScan flow cytometer (BD Biosciences) and data were processed
using FlowJo software.
Measurement of intracellular and circulating cytokines.
Intracellular expression of IL-17, IFNc and TGFb in CD4 and/or
CD25high cells was investigated using monoclonal antibodies
obtained from BD Bioscience, NJ, USA. After the staining
protocol, cells were fixed with 2% formaldehyde, stored at 4uC
and analyzed on flow cytometer the next day. Circulating and
supernatant cytokine levels were measured and analyzed with the
Bio-Plex system (Bio-Rad). TGFb in supernatants was measured
using the sensitive assay first described by Abe et al. [29] whereas
IFNc and IL-17 were measured using the Luminex platform. The
sensitivity of the cytokine assay was ,5 pg/ml for all cytokines
measured.
Statistical analysis. Values are shown throughout the paper
as mean6sem. Proportions of lymphocyte subpopulations were
compared using the Student’s t test for normally or not normally
distributed population where appropriate. Relationships between
different values were examined using Pearson’s correlation
coefficient and Spearman’s rank correlation tests. Difference
between groups were calculated using the Mann-Withney U test.
All statistical analyses were performed using Graphpad Prism
(GraphPad Prism 4.0 by Graph Pad software Inc.).
Results
CD4 positive T cells from SSc patients display an
activated phenotype
Previous reports have described an increased CD4/CD8 ratio
in SSc patients compared with healthy controls, however, recent
markers permit a more refined analysis of T cell phenotype [2,30].
Since effector T cells, suggested to be involved in SSc, arise from
the CD4+ T cells, we first investigated T cell phenotype and
activation. Consistent with previous studies, healthy controls
(n = 13) displayed a considerably lower CD4+/CD8+ ratio than
that observed in SSc patients (P,0.0001, figure 1a). We next
investigated whether CD4+ cells in SSc patients expressed T cell
activation markers, CD69 and GITR. Indeed, SSc patients on
average expressed significantly higher levels (P,0.0001) of CD69
on CD4+ effector T cells compared with those from healthy
controls (figure 1b). In contrast, CD69 expression was increased
on CD8+ cells only from those patients with the edcSSc, but not
on CD8+ cells from patients with lcSSc or ldcSSc (P,0.001). The
expression of GITR displayed a similar pattern being higher on
CD4+ cells from all subgroups of SSc patients compared to
controls (P,0.001). Highest expression was seen in patients with
edcSSc, with progressively less expression seen in patients with
ldcSSc and lcSSc, respectively (figure 1b, left panel). These
observations prompted us to further study the expression of these
activation markers on memory (CD45Ro) and naive T cells
(CD45Ra), since CD45Ro cells were previously found to be the
main producers of IL-17. Interestingly, the expression of CD69
was significantly higher on both CD45Ro and CD45Ra positive T
cells in all SSc patients compared with healthy controls, suggesting
that both these cell populations are activated in SSc (figure 1b
right panel).
Th17 cells are more frequent in SSc patients and IL-17 in
combination with IFNc and TGFb expression in T cells
discriminates SSc subsets
These observations showing activated T cells in patients with
SSc and recent findings of increased circulating levels of IL-17 and
IL-23 in patients with SSc, led us to examine the expression of the
IL-23 receptor (IL-23R) on T effector cells. Since it was recently
demonstrated that IL-23 is pivotal in the survival of Th17 cells,
increased expression of IL-23R might lead to enhanced Th17 cell
survival in patients with SSc [8,15,31,32]. Intriguingly, the
expression of IL-23R was markedly higher on CD3+, CD45Ro+
and CD45Ra cells from all SSc patients investigated (P,0.0001,
figure 2a). Notably, increased IL23R expression was observed on
CD4+ T cells of patients with both limited and diffuse cutaneous
SSc, including patients with ldSSc. Next, we investigated the
intracellular expression of IL-17 in CD45Ro and CD45Ra cells.
Consistent with the increased expression of IL-23R and markers of
activation (CD69 and GITR expression), the number of CD45Ro
cells that co-expressed IL-17 was significantly increased in all SSc
patients investigated (P,0.0001, Figure 2b). As previously
described, CD45Ra cells from healthy controls did not express IL-
17. In contrast, CD45Ra cells from SSc patients showed increased
numbers of IL-17 expressing cells that reached almost similar
levels as CD45Ro cells However, the mean fluorescence intensity
(MFI) of IL-17 in CD45Ro cells in SSc patients was clearly
increased compared to that observed in CD45Ra cells.
To further investigate cytokine expression of T cell from SSc
patients, we investigated the expression of TGFb and IFNc other
cytokines that have been implicated in SSc pathogenesis.
Comparison of the cytokine expression by T cells from patients
with the different SSc phenotypes revealed a clearly distinct
pattern. For instance, IFNc was highly expressed by both
CD45Ro and CD45Ra cells from patients with limited SSc, was
almost absent in CD45Ro cells from SSc patients with diffuse SSc
and expressed at intermediate levels by CD45Ra cells from diffuse
patients. In contrast, the expression of TGFb was increased in
both CD45Ro and CD45Ra cells from patients with limited and
late diffuse SSc but was normal in early diffuse patients. Based on
these observations we propose that certain cytokine patterns are
associated with certain SSc subtypes (Table 2).
Previously, we demonstrated that SSc patients have increased
levels of circulating T regulatory cells (submitted for publication).
Recently, two elegant studies revealed that neither Tregs nor Th17
cells are terminally differentiated but, under pressure of several
Th17 Cells in SSc
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cytokines or other immune cells, could switch phenotype [33].
Since this could be an explanation for concurrent increased
expression both of Tregs and Th17 in SSc, we investigated
whether CD25high expressing cells (Tregs) co-expressed IL-17.
Indeed, significant higher numbers of CD25high/IL-17-positive
cells were observed in SSc patients compared with healthy controls
(P,0.01, figure 2c).
To further extend and confirm our results showing increased
intracellular expression of IL-17 and IFNc in SSc, we next
measured the levels of IL-17 and IFNc in the supernatant of
CD3+ T cells isolated from healthy controls (n = 5), lcSSc patients
(n = 5), ldcSSc patients (n = 5) and edcSSc patients (n = 5).
Consistent with intracellular cytokine expression, T cells from all
three clinical phenotypes secreted high levels of IL-17 and IFNc
Figure 1. SSc patients have more and more activated CD4+ T cells compared to healthy controls. Panel A depicts the percentage of
CD4+ and CD8+ cells in the whole T cell pool (CD3+ cells) from healthy controls (n = 14), and SSc patients with the lcSSc (n = 12), ldcSSc (n = 11) and
edcSSc (n = 13) phenotype. The CD3+ cells were isolated using MACS bead isolation after which CD4 and CD8 positivity was analyzed using flow
cytometry. Panel B (left) depicts the percentage of CD4+ and CD8+ cells that were double-positive for the T cell activation markers CD69 and GITR.
For this aim a representative individual from each group was selected. In the right panel, the percentage of CD4-CD69, CD8-CD69, CD4-GITR, CD8-
GITR, CD45Ro-CD69 and CD45Ra-CD69 double positive cells is presented over the whole group of healthy donors (n = 14) and/or SSc patients (n = 36).
doi:10.1371/journal.pone.0005903.g001
Th17 Cells in SSc
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compared to T cells from healthy controls (figure 2d). The
pattern of altered secretion was also similar, with the highest levels
of IFNc secreted by T cells from patients with lcSSc, while the
highest levels of IFNc were secreted by T cells from patients with
early diffuse SSc.
SSc patients have normal levels of IL-17 but increased
levels of Th17 promoting cytokines IL-1a, IL-23 and IL-6
It has previously been reported that IL-17 levels are increased in
the circulation in SSc patients [15]. A major limitation of these
studies was the small sample size. This, together with our
experience that circulating IL-17 is very difficult to detect in
other autoimmune disorders such as rheumatoid arthritis, we
investigated the levels of IL-17 and IL-17 promoting cytokines in a
large cohort of SSc patients (n = 177) consisting out of 110 patients
with LSSc, 34 with ldSSc and 33 with the edSSc phenotype. As a
comparator group we used 28 healthy controls. When comparing
the level of IL-17 in SSc patients and healthy controls, IL-17 could
only be detected in a minority of the samples (9 of 177; Table 3,
Figure 3a) and was not detected more frequently in SSc patients
compared to controls. In contrast, the levels of IL-6 (53.669.7 vs.
5.463.4, P,0.0001), IL-1a (83.2611.2 vs. 1.261.1, P,0.002)
and IL-23 (49.167.3 vs. 5.360.6, P = 0.003) were significantly
higher in SSc as a whole compared with controls (Figure 3b–d).
Subgroup analysis revealed that IL-6 and IL-23 levels were equally
distributed among SSc phenotypes whereas IL-1a was significantly
increased in lSSc patients (P,0.001) only. An association between
clinical characteristics including the presence of autoantibodies,
disease duration and/or pulmonary involvement was not observed
(data not shown).
Discussion
We show here that patients with SSc have strikingly increased
frequencies of circulating Th17 cells. In addition, the combined
analysis of intracellular IL-17 with the expression of IFNc or
TGFb revealed a pattern among patients that correlated with the
different clinical SSc phenotypes. In line with these observations,
levels of Th17 inducing cytokines IL-6, IL-1a and IL-23 were
significantly higher in the circulation of SSc patients compared to
controls, although circulating IL-17 was not detectable. Similar to
our observations, the measurement of IL-17 in the circulation of
patients with rheumatoid arthritis and psoriasis, two conditions in
which IL-17 play a pivotal role in local pathology, was very
Table 2. Cytokine expression pattern in SSc clinical
phenotypes.
Phenotype/Cytokine expression IL-17 IFNc TGFb
Healthy controls low Low low
Limited SSc high High high
Late diffuse SSc high low high
Early diffuse SSc high intermediate low
doi:10.1371/journal.pone.0005903.t002
Figure 2. SSc patients express high levels of IL-17-positive T cells and the co-presence of IL-17 with either IFNc, IFNa or TGFb
reflects SSc phenotype. Panel A presents the percentage of IL-23R positive cells in the CD4+ positive pool of T cells (left panel) and CD45Ro and
CD45Ra positive cells (right panel) from healthy controls (n = 14), and SSc patients with the lcSSc (n = 12), ldcSSc (n = 11) and edcSSc (n = 13)
phenotype. Panel B shows the mean intracellular expression level of IL-17, IFNc and TGFb in CD4+ cells from each a representative individual from
each tested group (left side). On the right side, the mean percentage of CD45Ro-positive or CD45Ra-positive cells that express IL-17, IFNc or TGFb and
the mean intensity thereof are presented for the whole group of healthy controls (n = 14), and SSc patients with the lcSSc (n = 12), ldcSSc (n = 11) and
edcSSc (n = 13) phenotype. Panel C depicts the percentage of CD25high cells that co-express IL-17 in healthy controls and different SSc phenotypes (*
represents a p-value,0.01). Panel D represents the level of cytokines (IL-17 and IFNc) spontaneously secreted by CD3+ T cells from healthy controls
and SSc patients after 24 hrs of incubation. * P-value,0.0001, ** P-value,0.002, *** P-value,0.004.
doi:10.1371/journal.pone.0005903.g002
Table 3. Clinical characteristics of patients used for measurement of circulating cytokines.
Limited cutaneous SSc Late diffuse cutaneous SSc Early diffuse cutaneous SSc
Number 110 34 33
N females (%) 89 (81) 26 (76) 27 (82)
Age at onset 43.368.9 42.7611.7 41.369.8
Disease duration 11.267.1 8.165.3 1.560.8
ANA positivity 100% 77% 92%
Pulmonary hypertension 37% 19% 18%
Lung fibrosis 22% 47% 30%
Current Therapies
MMF 0% 7% 8%
Cyclophosphamide 0% 16% 33%
Prednisolone 14% 11% 23%
Hydroxychloroquine 3% 0% 0%
anti-IL-3 0% 0% 0%
Methotrexate 0% 0% 0%
Tacrolimus 0% 0% 0%
doi:10.1371/journal.pone.0005903.t003
Th17 Cells in SSc
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disappointing. Therefore, it is tempting to speculate that IL-17
might be an important cytokine locally in SSc.
In our study all SSc patients had increased frequencies of IL-17
positive cells and T cells cultured from SSc patients showed high
spontaneous production of IL-17. However, co-expression of IFNc
and TGFb together with IL-17 distinguished SSc phenotypes.
Patients with lcSSc expressed IL-17, IFNc and TGFb at the
highest levels. In particular, T cells from these patients expressed
higher levels of intracellular IFNc than patients with edcSSc.
Interestingly, in the lcSSc subgroup circulating levels of IL-1a
were significantly higher compared to other SSc phenotypes and
healthy controls, whereas IL-6 and IL-23 levels were elevated but
comparable in all SSc subgroups. Perhaps, higher IL-1a levels
skew the balance to more IL-17/IFNc double positive T cells.
The potential involvement of IL-17 in various autoimmune
diseases has sparked research aimed at the identification of the
forces driving Th17 priming. To date, accumulating evidence
point towards the essential role of DCs in orchestrating Th17
priming by the production of the driving factors for Th17
development, such as TGFb, IL-1a, IL-6 and IL-23. More
recently, it has become clear that Toll-like receptor mediated DC
activation is also implicated. In this light Gerosa and co-workers
demonstrated that the combination of specific Toll-like receptor
(TLR) ligands dramatically stimulated IL-23 production and skews
the immune response towards Th17 [34]. Although the role of
TLRs in SSc has not been subjected to extensive research, our
observations suggest a possible role for TLRs as a stimulus for the
increased numbers of Th17 cells in these patients. TLR are critical
for the innate immune response and bridge the innate and
adaptive immune response [35]. Many ligands have been
described for TLRs [36]. For TLR2 and TLR4 both exogenous
(derived from microorganisms) and endogenous (originating from
‘‘self’’ tissues) have been identified. In contrast, ligands identified
for the intracellular TLR3, TLR7, TLR8 and TLR9 mainly
Figure 3. Increased level of Th17 inducing cytokines in the circulation of SSc patients. Panel A depicts the presence of IL-17 in the
circulation of SSc patients and healthy controls. Panel B, C and D represents the levels of IL-6, IL-1a and IL-23, respectively. The circulating levels of IL-
17, IL-1a and IL-23 was measured by ELISA whereas IL-6 was studied by Bioplex assays.
doi:10.1371/journal.pone.0005903.g003
Th17 Cells in SSc
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comprise exogenous ligands including double and single stranded
RNA and CPG DNA. In this light it is interesting that several
endogenous ligands for TLR4 are present in the plasma of some
SSc patients ([37], unpublished results). We are currently
investigating the nature of endogenous TLR ligands in different
SSc phenotypes that could help to explain the observed differences
with respect to co-expression of several cytokines in conjunction
with IL-17. Recent observations from our group indicate an
aberrant TLR responses in SSc that are distinct among patients
having lcSSc, ldcSSc and edcSSc (manuscript submitted).
Little is known about the differentiation and maturation of IL-
17 positive cells in humans. In contrast with the initial reports, we
demonstrate that the Th17 phenotype is not confined to CD4+
effector cells but also includes a substantial number of naı¨ve cells
(CD45Ra) [11]. The latter is in line with a recent report
investigating Th17 cells in seronegative spondylarthropathy [22].
As explained in this report, potential differences between studies
could be explained by slightly differences in isolation protocols.
However, an important other explanation might be that the
factors that drive Th17 among different diseases differ also with
respect to the CD4+ subpopulations that are activated.
Taken together, although the underlying mechanisms that
explain the distinct patterns of intracellular cytokine expression
among SSc phenotypes need to be identified, these patterns
suggest distinct immune dysregulation in dcSSc versus lcSSc and
in early versus late disease in dcSSc. These insights open novel
avenues for research aimed at identifying pathogenic pathways
and therapeutic targets.
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